FDA Greenlights Privosegtor Path for MS Relapses, IND Filing Set for Q4
OCS is trading near its 52-week low of $10.52 (6.9% above the low) on light trading volume (0.3× avg).
Summary
Oculis received positive FDA pre-IND feedback for Privosegtor in acute MS relapses, a new indication beyond the ongoing PIONEER optic neuritis program. The FDA confirmed no additional preclinical work is needed and supported a 3-month primary endpoint with the same dosing as PIONEER-1. An IND submission is planned for Q4 2026, with an R&D day later this year to detail the pivotal program. This expands the neuroprotective pipeline into a large market—~170,000 U.S. MS relapses annually—with no approved neuroprotective therapies. It follows the May SPA agreement for PIONEER-1 and the OCS-01 Phase 3 failure, refocusing value on Privosegtor. The clear regulatory path and near-term catalyst could shift sentiment after the recent setback.
At the time of this announcement, OCS was trading at $11.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $646.6M. The 52-week trading range was $10.52 to $34.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.